Pfizer (NYSE:PFE - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.880. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $63.3 billion.
Pfizer stock opened at $25.26 on Tuesday. The stock has a market capitalization of $143.15 billion, a P/E ratio of 34.14, a price-to-earnings-growth ratio of 0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a fifty day moving average of $27.09 and a 200-day moving average of $28.25.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) earnings per share. The firm's quarterly revenue was up 31.2% on a year-over-year basis. On average, sell-side analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.81%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is 227.03%.
A number of equities research analysts recently commented on the stock. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $32.15.
View Our Latest Stock Report on Pfizer
In other news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.